This Viewpoint presents the components of the payment model and the implementation challenges among the Center for Medicare and Medicaid Innovation, state Medicaid agencies, patients, and manufacturers.

Me gusta

Guardar

Me gusta

Guardar

Advancing Access to Cell and Gene Therapies in Medicaid | Synapse

Cite This Study

Kannarkat et al. (Wed,) studied this question.

synapsesocial.com/papers/68e68e7db6db643587615dab https://doi.org/https://doi.org/10.1001/jama.2024.6224

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Examining Misaligned Incentives for Payers and Manufacturers in Value-Based Pharmaceutical Contracts2019 · 9 citations
2<p>Development of a Severity Classification System for Sickle Cell Disease</p>

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Examining Misaligned Incentives for Payers and Manufacturers in Value-Based Pharmaceutical Contracts2019 · 9 citations
2<p>Development of a Severity Classification System for Sickle Cell Disease</p>

2020 · 45 citations

3Risk factors for mortality in adult patients with sickle cell disease: a meta-analysis of studies in North America and Europe2017 · 134 citations

4A network model to predict the risk of death in sickle cell disease2007 · 159 citations

5Somatic Symptom Burden in Adults with Sickle Cell Disease Predicts Pain, Depression, Anxiety, Health Care Utilization, and Quality of Life: The PiSCES Project2011 · 92 citations